PDF DatasheetHuman Anti-CD45RO Antibody Product Attributes
CD45RO Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in CD45RO antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, germinal center cells in the lymph node, non-germinal center cells in the lymph node, cells in the red pulp in spleen, cells in the white pulp in spleen, germinal center cells in the tonsil and non-germinal center cells in the tonsil. More moderate antibody staining intensity was present in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, germinal center cells in the lymph node, non-germinal center cells in the lymph node, cells in the red pulp in spleen, cells in the white pulp in spleen, germinal center cells in the tonsil and non-germinal center cells in the tonsil. Low, but measureable presence of CD45RO could be seen in. We were unable to detect CD45RO in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD45RO expression as measured by anti-CD45RO antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | +++ | – | – | – | – | – | – | – | – | – | – |
| PTPRC Variability | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| CD45RO General Information | |
|---|---|
| Curated Database and Bioinformatic Data | |
| Gene Symbol | PTPRC |
| Entrez Gene ID | 5788 |
| Ensemble Gene ID | ENSG00000081237, ENSG00000262418 |
| RefSeq Protein Accession(s) | XP_006711537, XP_006711536, XP_006711535, NP_563578, NP_001254727, NP_002829 |
| RefSeq mRNA Accession(s) | XM_006711473, XM_006711474, NM_080921, NM_080922, NM_001267798, NM_002838, XM_006711472, NR_052021 |
| RefSeq Genomic Accession(s) | NG_007730, NC_000001, NW_003315907, NC_018912 |
| UniProt ID(s) | X6R433, A0A0A0MT22, P08575, M9MML4 |
| UniGene ID(s) | X6R433, A0A0A0MT22, P08575, M9MML4 |
| HGNC ID(s) | 9666 |
| Cosmic ID(s) | PTPRC |
| KEGG Gene ID(s) | hsa:5788 |
| PharmGKB ID(s) | PA34011 |
| General Description of CD45RO. | |
| The UCHL1 antibody reacts with the human CD45 isoform known as CD45RO, a protein tyrosine phosphatase of 220 kDa. CD45 is one of the most abundant hematopoietic markers, and is expressed on all leukocytes (the Leukocyte Common Antigen, LCA). Various isoforms are generated and expressed in cell-specific patterns. With their broad cell distribution, CD45 isoforms are critical for many leukocyte functions, regulating signal transduction and cell activation associated with the T cell receptor, B cell receptor, and IL-2 receptor. Other forms of CD45, with restricted cellular expression, include CD45R (B220), CD45RA and CD45RB.The UCHL1 antibody is widely used as a marker for human CD45RO expression on thymocytes, activated memory T cells, monocytes, macrophages and granulocytes. The antibody is reported to be cross-reactive for Chimpanzee CD45RO. | |
Selected References
Limitations and Warranty
| Size | |
|---|---|
| Tag | APC, APC-Cy7, Biotin, FITC, PE, PerCP-Cy5.5, Qfluor™ 630, Unconjugated |
| Buffer and Stabilizer | 10 mM NaH2PO4, 150 mM NaCl, 0.09% NaN3, 0.1% gelatin, pH7.2, 10 mM NaH2PO4, 150 mM NaCl, 0.09% NaN3, pH 7.2 |
| Product Type | |
| Host | |
| Isotype | |
| Applications | |
| Species | |
| Mass Spec Validated? |
Only logged in customers who have purchased this product may leave a review.
There are no reviews yet.